Project Grant R03CA308672
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $169K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Weill Medical College of Cornell University a $683,979 Project Grant under the Cancer Biology Research program (CFDA 93.396) for research investigating the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The award, effective June 1, 2025, through April 30, 2030, will deliver fundamental research aimed at understanding how specific molecular features in early, untreated prostate cancer...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $204,027 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025 through July 31, 2030. This award supports the development and application of advanced single-cell and spatial technologies designed to link clonal genotypes with phenotypes during cancer evolution. The project addresses a critical gap in cancer research by...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $472,730 project grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025, through July 31, 2030. This five-year project investigates the role of the tumor suppressor KEAP1 (Kelch-like ECH-associated protein 1) in antitumor immunity, with specific focus on understanding how loss-of-function KEAP1 mutations contribute to immune...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $401,829 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025, through August 31, 2028. The award funds the development of innovative single-cell molecular footprinting methodologies to map chromatin-associated protein activity in cancer cells. Specifically, the research introduces Docking & Deamination Plus...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Weill Medical College of Cornell University a $656,304 Project Grant effective July 10, 2025, under the Cancer Biology Research program (CFDA 93.396) to support fundamental research into signal transduction mechanisms related to mammalian target of rapamycin complex 1 (mTORC1) and p70 S6 kinase 1 (S6K1) signaling in cancer cells. The research project, with completion targeted for April 30, 2030, will utilize integrated...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $1,006,599 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2029. This award supports the expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens through the Meyer Cancer Center (MCC) at Weill Cornell Medicine and NewYork-Presbyterian. The project...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $198,164 Project Grant to Weill Medical College of Cornell University under the Cancer Research Manpower program (CFDA 93.398) on September 26, 2025, with an ultimate completion date of April 6, 2027. This award supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The funded project, "Genomic Instability in Lung...
- Federal Grant Award Summary Duke University received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion scheduled for July 31, 2029. This research project, titled "Understanding and Targeting Epigenetic Regulation of Immune Evasion in Prostate Cancer," will investigate how epigenetic mechanisms—specifically through the TNRC18 protein—regulate immune evasion in...